Tibotec Presents Positive Interim Findings From Phase IIa Hepatitis Study
Posted on: Monday, 3 November 2008, 09:00 CST
Tibotec, a pharmaceutical R&D company, has presented positive interim data from Phase IIa hepatitis study which demonstrated the antiviral activity of TMC435, an investigational protease inhibitor being developed by the company for the treatment of chronic hepatitis C virus infection.
In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive hepatitis C virus plus (HCV+), genotype 1, patients (once daily dose of 25mg or 75mg TMC435 versus placebo), both doses showed dose-dependent antiviral activity.
TMC435 was administered in combination with PegIFNalpha-2a/RBV (triple therapy) for 28 days or as monotherapy for seven days and, thereafter, in combination with PegIFNalpha-2a/RBV (triple therapy) for three weeks. There were neither serious adverse events, nor grade 3 or 4 adverse events, related to TMC435 or any safety-related treatment discontinuations during this 28-day treatment period.
Roger Pomerantz, president of R&D at Tibotec, said: "Tibotec is committed to evaluating the safety and efficacy of TMC435 in clinical studies to determine its potential use in people with HCV. This is an important step in our mission of addressing treatment challenges of infectious diseases, including HCV, HIV and tuberculosis."
Source: Datamonitor
Related Articles
- Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
- National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial With Telaprevir in Treatment-Failure HCV Patients
- Early Treatment Key to Treat Hepatitis C
- Despite Morbidity Associated With Hypertension, Almost 65% of Newly Diagnosed Patients Do Not Receive Drug Treatment in the First 360 Days of Their Diagnosis
- Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV
- ViroPharma Announces That Treatment With HCV-796 Reduces Hepatitis C Virus Levels
- InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
- InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders
 |
 |
User Comments (0)
RSS Feeds